^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QLS1103

    i
    Other names: QLS1103
    Associations

    News

    Trials
    Company:
    Qilu Pharma
    Drug class:
    PARP7 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=148, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1 trial • Metastases
    |
    QLS1103